OncoSec Medical Inc (ONCS)

1.26
NASDAQ : Health Care
Prev Close 1.28
Day Low/High 1.21 / 1.28
52 Wk Low/High 1.19 / 3.49
Avg Volume 173.30K
Exchange NASDAQ
Shares Outstanding 19.73M
Market Cap 25.26M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

OncoSec Announces Key Corporate Initiatives At Inaugural Investor & Analyst Day On November 17, 2016

- OncoSec is Executing on a Melanoma Registration-Directed Clinical Program with Immunopulse® IL-12 and Anti-PD-1 Therapy

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

OncoSec To Host First Quarter Financial Results Conference Call On December 8, 2016

Company to Host Investor and Analyst Day on November 17, 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

OncoSec Announces Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016

Company to Host Investor and Analyst Day on November 17, 2016

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

Here's a technical look at how to trade five stocks that are ready to break out and trade higher from current levels.

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

OncoSec Presents Preliminary Findings From Head And Neck Phase II Clinical Trial At EUROGIN 2016 Conference

ImmunoPulse™ IL-12 May Lead to Increased CD8+ T-Cell Infiltration in Patients with Squamous Cell Carcinoma of the Head and Neck, Suggesting That It May Prime Responses to Anti-PD-1 Blockade

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

OncoSec Collaborators Present Results Of Novel T-Cell Exhaustion Marker To Predict Response To Anti-PD-1 Monotherapy

The combination of OncoSec's ImmunoPulse™ IL-12 and pembrolizumab is the first clinical trial to use this assay to select specific patients, who are unlikely to respond to monotherapy with anti-PD-1 agents

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting

Preclinical findings demonstrate that intratumoral electroporation activates tumor neoantigen-specific immune responses